Advertisement

Annals of Hematology

, Volume 96, Issue 3, pp 355–362 | Cite as

Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012

  • Luiz Claudio Santos Thuler
  • Maria S. Pombo-de-OliveiraEmail author
Original Article

Abstract

The WHO classification that defines subtypes of acute myeloid leukaemias (AMLs) is relatively unexplored at the population-based level. This study aimed to examine the frequency of acute promyelocytic leukaemia (APL or AML-M3) in Brazil. Data were extracted from 239 cancer centres (2001–2012) and categorized according to the International Classification of Diseases for Oncology (CID-O 3.0) and WHO classification (n = 9116). CID-O3 code 9866 identified 614 APL patients. AML not otherwise specified (NOS) was frequent, and the APL group represented the main subtype specified. The mean age of APL was lower than that of other AMLs (31.5, standard deviation (SD) 18.6 versus 40.9, SD 24.6; p < 0.001); there was a high frequency of APL in the 13–21-year-old (11.8 %) and ≤12.9-year-old (6.4 %) age groups. Time taken to begin treatment (as ≤14 days versus >14 days) and induction death rate were lower in APL than in other AML subtypes (p < 0.001). This report provides additional evidence on the distribution of APL among cases of AML in Brazil.

Keywords

Hospital-based study Childhood and adults Acute myeloid leukaemia Acute promyelocytic leukaemia Brazil 

Notes

Acknowledgments

MSPO has been supported by FAPERJ #E026/101.562/2010; the project was partially funded by grants from FAPERJ#E026/110.169/2013.

Authors’ contributions

LCT and MSPO contributed equally in the manuscript description.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Deschler B, Lubbert M (2006) Acute myeloid leukemia: epidemiology and etiology. Cancer 107:2099–2107CrossRefPubMedGoogle Scholar
  2. 2.
    Estey EH (2013) Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88:318–327CrossRefPubMedGoogle Scholar
  3. 3.
    Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103(30):620–625CrossRefPubMedGoogle Scholar
  4. 4.
    Bennett JM, Catovsky D, Daniel MT et al (1985) Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 103(3):460–462CrossRefPubMedGoogle Scholar
  5. 5.
    Bennett JM, Catovsky D, Daniel MT et al (1991) Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78:325–329CrossRefPubMedGoogle Scholar
  6. 6.
    Creutzig U, van den Heuvel-Eibrink MM, Gibson B et al (2012) Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120:3187–3205CrossRefPubMedGoogle Scholar
  7. 7.
    Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474CrossRefPubMedGoogle Scholar
  8. 8.
    Vardiman JW, Thiele J, Arber DA et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951CrossRefPubMedGoogle Scholar
  9. 9.
    Swerdlow SH, Campo E, Harris NL et al (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer, LyonGoogle Scholar
  10. 10.
    Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM (2012) Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 119:34–43CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 (2004) Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base No. 5 Version 2.0. IARC-Press, LyonGoogle Scholar
  12. 12.
    Groves FD, Linet MS, Devesa SS (1995) Patterns of occurrence of the leukaemias. Eur J Cancer 31A:941–949CrossRefPubMedGoogle Scholar
  13. 13.
    Douer D, Santillana S, Ramezani L et al (2003) Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene. Br J Haematol 122:563–570CrossRefPubMedGoogle Scholar
  14. 14.
    Ribeiro RC, Rego E (2006) Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program 2006(1):162–168Google Scholar
  15. 15.
    Howlader N, Noone AM, Krapcho M et al (2013) SEER Cancer Statistics Review, 1975–2010. National Cancer Institute, BethesdaGoogle Scholar
  16. 16.
    Chen Y, Kantarjian H, Wang H, Cortes J, Ravandi F (2012) Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer 118:5811–5818CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116(19):3724–3734CrossRefPubMedGoogle Scholar
  18. 18.
    Gregory J, Feusner J (2009) Acute promyelocytic leukemia in childhood. Curr Oncol Rep 11:439–445CrossRefPubMedGoogle Scholar
  19. 19.
    Biondi A, Rovelli A, Cantu-Rajnoldi A et al (1994) Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). Leukemia 8:1264–1268PubMedGoogle Scholar
  20. 20.
    Gomez SM, Schuttenberg V, Armendariz H et al (2001) Childhood acute leukemia: a single institution experience in La Plata, Argentina. Med Pediatr Oncol 36:383–385CrossRefPubMedGoogle Scholar
  21. 21.
    Jacomo RH, Melo RA, Souto FR et al (2007) Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Haematologica 92:1431–1432CrossRefPubMedGoogle Scholar
  22. 22.
    Matasar MJ, Ritchie EK, Consedine N, Magai C, Neugut AI (2006) Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. Eur J Cancer Prev 15:367–370CrossRefPubMedGoogle Scholar
  23. 23.
    Hitzler JK, Zipursky A (2005) Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 5:11–20CrossRefPubMedGoogle Scholar
  24. 24.
    Appelbaum FR, Gundacker H, Head DR et al (2006) Age and acute myeloid leukemia. Blood 107:3481–3485CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Vigitel Brazil 2013 (2014) Protective and risk factors for chronic diseases by telephone survey. Brasilia/DF: Health Minister; URL:http://biavati.files.wordpress.com/2014/05/vigitel-2013.pdf. Accessed 30 Jan 2016
  26. 26.
    Rego EM, Kim HT, Ruiz-Arguelles GJ et al (2013) Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood 121:1935–1943CrossRefPubMedGoogle Scholar
  27. 27.
    Park JH, Qiao B, Panageas KS et al (2011) Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 118:1248–1254CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Nagendra S, Meyerson H, Skallerud G, Rosenthal N (2002) Leukemias resembling acute promyelocytic leukemia, microgranular variant. Am J Clin Pathol 117:651–657CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Luiz Claudio Santos Thuler
    • 1
  • Maria S. Pombo-de-Oliveira
    • 2
    • 3
    Email author
  1. 1.Clinical Epidemiology, Research Center, Rua Andre Cavalcanti, 37-Instituto Nacional de Câncer, INCARio de JaneiroBrazil
  2. 2.Pediatric Hematology-Oncology Program, Research Center, Instituto Nacional de Câncer, INCARio de JaneiroBrazil
  3. 3.Rio de JaneiroBrazil

Personalised recommendations